日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer

一项随机 II 期研究，比较 sapanisertib 联合紫杉醇与单用紫杉醇治疗晚期、复发性或持续性子宫内膜癌女性患者的疗效。

期刊:Gynecologic Oncology
影响因子:4.1
doi:10.1016/j.ygyno.2023.09.013
Han, Sileny N; Oza, Amit; Colombo, Nicoletta; Oaknin, Ana; Raspagliesi, Francesco; Wenham, Robert M; Braicu, Elena Ioana; Jewell, Andrea; Makker, Vicky; Krell, Jonathan; Alía, Eva María Guerra; Baurain, Jean-François; Su, Zhenqiang; Neuwirth, Rachel; Vincent, Sylvie; Sedarati, Farhad; Faller, Douglas V; Scambia, Giovanni
肿瘤
子宫内膜癌
肿瘤免疫
发表日期：2023
文献求助 收藏

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine

在东亚急性髓系白血病或骨髓增生异常综合征患者中评估培沃地司他单药及联合阿扎胞苷治疗的安全性、药代动力学和活性的1/1b期研究

期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-022-01264-w
Handa, Hiroshi; Cheong, June-Won; Onishi, Yasushi; Iida, Hiroatsu; Kobayashi, Yukio; Kim, Hyeoung-Joon; Chiou, Tzeon-Jye; Izutsu, Koji; Tsukurov, Olga; Zhou, Xiaofei; Faessel, Helene; Yuan, Ying; Sedarati, Farhad; Faller, Douglas V; Kimura, Akiko; Wu, Shang-Ju
白血病
发表日期：2022
文献求助 收藏

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

一项随机II期临床试验，比较Sapanisertib±TAK-117与依维莫司在接受VEGF靶向治疗后的晚期肾细胞癌患者中的疗效。

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyac192
Choueiri, Toni K; Porta, Camillo; Suárez, Cristina; Hainsworth, John; Voog, Eric; Duran, Ignacio; Reeves, James; Czaykowski, Piotr; Castellano, Daniel; Chen, Jingjing; Sedarati, Farhad; Powles, Thomas
肿瘤
肿瘤免疫
细胞生物学
肾癌
EGF
VEGF
发表日期：2022
文献求助 收藏

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

Sapanisertib (TAK-228) 在东亚晚期非血液系统恶性肿瘤患者中的 I 期研究

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-021-00855-w
Shimizu, Toshio; Kuboki, Yasutoshi; Lin, Chia-Chi; Yonemori, Kan; Yanai, Tomoko; Faller, Douglas V; Dobler, Lwona; Gupta, Neeraj; Sedarati, Farhad; Kim, Kyu-Pyo
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

更正：一项针对东亚晚期非血液系统恶性肿瘤患者的Sapanisertib (TAK-228) 1期研究

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-022-00881-2
Shimizu, Toshio; Kuboki, Yasutoshi; Lin, Chia-Chi; Yonemori, Kan; Yanai, Tomoko; Faller, Douglas V; Dobler, Lwona; Gupta, Neeraj; Sedarati, Farhad; Kim, Kyu-Pyo
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

一项评估利福平对晚期实体瘤患者体内 NEDD8 激活酶抑制剂 pevonedistat 药代动力学影响的 1 期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-022-01286-8
Zhou, Xiaofei; Vaishampayan, Ulka; Mahalingam, Devalingam; Harvey, R Donald; Chung, Ki Young; Sedarati, Farhad; Dong, Cassie; Faller, Douglas V; Venkatakrishnan, Karthik; Gupta, Neeraj
发表日期：2022
文献求助 收藏

Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

涵盖亚洲的pevonedistat全球开发：临床药理学和转化研究为开展3期多区域临床试验奠定基础

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.12972
Zhou, Xiaofei; Friedlander, Sharon; Kupperman, Erik; Sedarati, Farhad; Kuroda, Shingo; Hua, Zhaowei; Yuan, Ying; Yamamoto, Yuka; Faller, Douglas V; Haikawa, Kazue; Nakai, Katsuhiko; Bowen, Sharon; Dai, Yi; Venkatakrishnan, Karthik
发表日期：2021
文献求助 收藏

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

一项评估[(14)C]-pevonedistat（一种NEDD8激活酶抑制剂）在晚期实体瘤患者中的质量平衡、药代动力学和排泄情况的I期研究

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-020-01017-x
Zhou, Xiaofei; Sedarati, Farhad; Faller, Douglas V; Zhao, Dan; Faessel, Hélène M; Chowdhury, Swapan; Bolleddula, Jayaprakasam; Li, Yuexian; Venkatakrishnan, Karthik; Papai, Zsuzsanna
发表日期：2021
文献求助 收藏

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

mTORC1/2抑制剂sapanisertib（TAK-228）治疗晚期实体瘤的I期研究，并计划在肾癌、子宫内膜癌或膀胱癌中进行扩展研究。

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-020-01041-x
Voss, Martin H; Gordon, Michael S; Mita, Monica; Rini, Brian; Makker, Vicky; Macarulla, Teresa; Smith, David C; Cervantes, Andrés; Puzanov, Igor; Pili, Roberto; Wang, Ding; Jalal, Shadia; Pant, Shubham; Patel, Manish R; Neuwirth, Rachel L; Enke, Aaron; Shou, Yaping; Sedarati, Farhad; Faller, Douglas V; Burris, Howard A 3rd
肿瘤
mTOR
子宫内膜癌
肿瘤免疫
肾癌
ORC1
膀胱癌
发表日期：2020
文献求助 收藏

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

一项针对晚期实体瘤患者的Ib期研究，评估了NEDD8激活酶抑制剂pevonedistat联合多西他赛、卡铂和紫杉醇或吉西他滨的疗效。

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-018-0610-0
Lockhart, A Craig; Bauer, Todd M; Aggarwal, Charu; Lee, Carrie B; Harvey, R Donald; Cohen, Roger B; Sedarati, Farhad; Nip, Tsz Keung; Faessel, Hélène; Dash, Ajeeta B; Dezube, Bruce J; Faller, Douglas V; Dowlati, Afshin
发表日期：2019
文献求助 收藏